Perhaps the biggest sticking point in the debate around remote imaging operations relates to the bedside. If a technologist is running the exam remotely, who is tending to patients on-site? 

Lauren Beene, MD, and Valerie Fouts-Fowler, MD, allege in a lawsuit that Ohio-based University Hospitals fired them for expressing concerns through a chat app. The health system accused the duo of misusing internal communications for personal gain. 

The director of the National Institutes of Health and his principal deputy are touting their success at ‘curing’ the agency of its self-inflicted DEI disability. 

Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026.

Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

Published Friday in JAMA, scientists recently explored a risk-based mammography tactic that tailors regular imaging regimens to each individual’s danger of developing the disease. 

Alleged transgressions took place between February and August, including the FDA rejecting Telix’s application for a new brain cancer imaging agent. 

DECT systems allow for a contrast dose reduction of up to 25% during computed tomography pulmonary angiography exams.